Imclone systems (IMCL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL)

IMCL 0.159

0.0%

Oct 5 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cacaito who wrote (2022)	2/14/2002 4:21:25 PM
From: IRWIN JAMES FRANKEL	Read Replies (1) of 2515

"Case is building up" What case? Not BMY. Failure to inform Merck of the FDA RTF (in advance of what?) is meaningless to any claim that BMY might assert. Merck, how is it damaged? IMCL disclosed the news to everyone promptly. Do you suggest that material inside information, (the FDA RTF) even if required by a contract, should be disclosed to Merck prior to other shareholders? I don't see that. BMY's only fruitful approach is to work with IMCL to get Erbitux approved. That will build value. Infighting and lawsuits ONLY make money for the lawyers. But that's OK - lawyers are wonderful people. (At least that is what people think when they need us.) <g> ij

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next